Joel Farley
Document Actions
Farley JF, Devine JD, Hadsall RS. “Professional implications of the expansion of pharmacy-based medical clinics”. Journal of the American Pharmacists Association (In press)
Lu YJ, Farley JF, Hansen RA. (2006) “Promotion and market share in the proton pump inhibitor market: A case study”. The Journal of Pharmaceutical Marketing and Management. (In press)
Farley JF, Cline RR, Gupta K. (2006) “Racial variation in antiresorptive medications use: results from the 2000 Medical Expenditure Panel Survey (MEPS)”. Osteoporosis International. 17(3): 395-404.
Devine JW, Cline RR, Farley JF. (2006) “What is the benefit of a market without generic biologics? the uncertain future of generic competition in the biopharmaceutical market.” Journal of the American Pharmacists Association. 46(2): 193-201.
Farley JF, Harley CR, Devine JW. (2006) “A comparison of comorbidity measurements to predict health expenditures.” American Journal of Managed Care. 12(2): 110-117.
Devine JW, Farley JF, Hadsall RS. (2005) “Patterns and predictors of prescription medication use in the management of headache.” Headache: The Journal of Head and Face Pain. 45(9):1171-1180.
Cline RR, Farley JF, Hansen RA, Schommer JC. (2005) “Osteoporosis beliefs and antiresorptive medication use.” Maturitas. 50:196-208.
Farley JF, Cline RR, Hansen RA. (2004) “Resorptive drug use patterns among Minnesota females: results of a statewide survey.” American Journal of Health-System Pharmacy. 61:1577-1585.